CURRENT APPROACHES TO THERAPY FOR INDOLENT NON-HODGKINS-LYMPHOMA

Progress in the treatment of indolent non-Hodgkin's lymphoma has been slow and the disease remains incurable despite the relatively long med ian survival of patients. Decades of clinical trials resulted in stand ard chemotherapy regimens that produced relatively identical results. Two recent events, however, offer great optimism for future therapeuti c progress. First, our understanding of the biology and immunology of lymphoid malignancies has increased remarkably. Second, there are a la rge number of new and unique chemotherapeutic and biological agents en tering into clinical trials.